Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC

This article was originally published in The Gray Sheet

Executive Summary

Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA

You may also be interested in...



EuroPCR 2007 Results Join Growing Mix Of Stent Safety Data

Drug-eluting stent makers continue to battle it out with the release of the latest safety data at the May 22-25 EuroPCR meeting in Barcelona, Spain

EuroPCR 2007 Results Join Growing Mix Of Stent Safety Data

Drug-eluting stent makers continue to battle it out with the release of the latest safety data at the May 22-25 EuroPCR meeting in Barcelona, Spain

Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years

Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study

Related Content

UsernamePublicRestriction

Register

MT024631

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel